



# ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: [www.americasblood.org](http://www.americasblood.org)

2025 #8

March 3, 2025

**INSIDE:**

WORD IN WASHINGTON .....2  
 PEOPLE.....3  
 MEMBER NEWS.....3  
 BRIEFLY NOTED.....4  
 28<sup>th</sup> Annual Awards of Excellence Recipients to Be Honored at the ABC Annual Meeting .....5  
 ADRP Trends in Donor Relations Study Opens.6  
 Registration Open for ADRP Webinar: "Positive Impacts of a Global Pandemic: What Changed?" .....6  
 Registration Is Open for March 28<sup>th</sup> SMT Journal Club Webinar.....6  
 Still Time Register for the 2025 ABC Annual Meeting .....6  
 Register for the 2025 ADRP Annual Conference.....7  
 INFECTIOUS DISEASE UPDATES .....7  
 GLOBAL NEWS .....8  
 COMPANY NEWS .....9  
 CALENDAR.....10  
 POSITIONS.....11

## Transfusion Laboratory Insights on Red Blood Cell Inventory Management Published

A study [published](#) in *Transfusion Medicine* shares insights and challenges into red blood cell (RBC) inventory management. The authors of the paper explained that their study aims to, “provide complementary data to quantitative models that incorporate human factors in the inventory management of RBCs, particularly Group O negative RBCs.” The study included interviews with 16 individuals, “with representatives from the same institution interviewed simultaneously in a focus group style conversation using the same semi-structured interview guide.”

The researchers noted their semi-structured interview guides were co-developed with technologists, technical leads, medical directors, and data analytics leads. Interviews occurred via Zoom from September to November 2022. The paper discovered that five themes impacted technologist decision-making on RBC inventory management:

- “[b]alancing logistics, local policies, and human factors in inventory management;
- [v]arying perceptions of redistribution and its unintended consequences;
- [g]uidance on the appropriate usage of O negative RBCs and management;
- [d]efining efficiency and the performance measures of inventory management; [and]
- [c]ultural barriers to inventory model integration in healthcare.”

The authors explained that their key takeaways included that the top three inventory practices are:

- [u]sing group O positive RBCs for emergency use;
- [r]edistribution and prioritiz[ing] fresher RBCs for rural/remote sites; [and]
- [t]ransfusion of O negative RBCs to typed non-O patients to avoid expiry.”

Their research also found that the challenges managing O-negative RBCs are:

- “the demand for O negative RBCs strains its supply, so that O positive RBCs are often used as substitute universal donor RBCs;
- predicting patient use;
- rural/remote sites historically do not use much inventory but need to be prepared for an emergency and often must carry group O blood because of lack of testing in those areas/lack of blood bank specific staffing;
- inventory is stockpiled, aged, and then used to avoid expiry;
- redistribution has the unintentional result of facilitating overordering;
- varying opinions of the optimal use of O negative RBCs; [and]


(continued on page 2)



## Insights on RBC Inventory Management (continued from page 1)

- changing clinical and inventory practices to help better manage O negative is difficult.”

The authors used the findings to develop a flow chart of inventory management that they believe, “can be generali[z]ed to other jurisdictions [since it was built] to include a network of hospitals and redistribution of group O negative RBCs [and] is calibrated to real-world data and uses inventory management performance indicators identified from technologists and technical leads.” The researchers concluded that, “[t]hrough our qualitative methods, we have identified key factors for understanding practices in RBC inventory management for hospital blood banks catering to diverse needs across a jurisdiction spanning a large geographic area with numerous rural/remote patient populations. The insights [gained and reported] can inform appropriate inventory levels, ensuring equity in resource allocation for rural/remote blood banks with varying inventory usage.”



**Citation:** Dhahan, J., Morrison, D., Shih, A. *et al.* “[Red blood cell inventory management: Insights from transfusion laboratory technologists in British Columbia, Canada.](#)” *Transfusion Medicine*. 2025 💧

## WORD IN WASHINGTON

**The Senate Health, Education, Labor & Pensions (HELP) Committee will [hold](#) a confirmation hearing on March 6<sup>th</sup> for U.S. Food and Drug Administration (FDA) Commissioner Nominee Martin Makary, MD MPH.** He is a surgeon, public policy researcher, and chief of Islet Transplant Surgery at Johns Hopkins.

(Source: Senate HELP Committee [News Release](#), 2/27/25)

**National Institutes of Health (NIH) Director Nominee Jayanta Bhattacharya, MD, PhD will [testify](#) before the Senate HELP Committee on March 5<sup>th</sup> during a confirmation hearing.** He is a physician and professor of Medicine at Stanford University.

(Source: Senate HELP Committee [News Release](#), 2/26/25) 💧

The *ABC Newsletter* (ISSN #1092-0412) is published by America’s Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2025 by America’s Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher (ABC members need not obtain prior permission if proper credit is given).

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognizes the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies, and programs that increase awareness about the need for blood donation; and serve as a thought leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

### America’s Blood Centers

Chief Executive Officer: Kate Fry  
 Chief Medical Officer: Jed Gorlin  
 Editor: Mack Benton  
 Subscriptions Manager: Leslie Maundy  
**Annual Subscription Rate: \$420**

Send subscription queries to  
[memberservices@americasblood.org](mailto:memberservices@americasblood.org)  
 America’s Blood Centers  
 1717 K St. NW, Suite 900, Washington, DC 20006  
 Phone: (202) 393-5725  
 Send news tips to [newsletter@americasblood.org](mailto:newsletter@americasblood.org).



## PEOPLE



*(Left) ABC's Kate Fry and Diane Calmus join James Berger (Center) and retired former ABC employees Toni Mattoch and Ruth Sylvester (Right) for a photo during his retirement celebration.*

**James Berger MS, MT(ASCP) SBB** has retired as senior advisor for Blood and Tissue Policy for the U.S. Department of Health and Human Services (HHS) Assistant Secretary of Health, Office of Infectious Disease and HIV/AIDS Policy. In this role, Mr. Berger served as the designated federal officer for the HHS Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA). In 2023 he was honored with an “Outstanding Leadership Award” from the Office of the Assistant Secretary for Health for his and his team’s dedication in helping to ensure a safe and available blood supply in the U.S. He was also a recipient of America’s Blood Centers (ABC) Blood Community Advocate of the Year award in 2015. ABC congratulates Mr. Berger and thanks him for his years of service.

## MEMBER NEWS

**Vitalant** recently [joined](#) Velico Inc.’s Blood Center Education Program (BCEP), “to explore the potential integration of spray dried plasma production into its blood center component operations.” According to a news release, this collaboration affords Vitalant the opportunity to, “gain hands on experience with Velico’s FrontlineODP™ Spray Dried Plasma System, a cutting-edge technology designed to empower regional blood centers with the capability to produce and distribute spray dried plasma.” Vitalant President and Chief Executive Officer (CEO) Dave Green explained in the news release, “[p]articipating in BCEP aligns perfectly with our commitment to delivering lifesaving blood whenever and wherever it is needed. As a recognized leader in transfusion medicine, we continuously seek advancements that enhance the quality and reach of our blood services.” The spray dried plasma system has not yet been approved by the U.S. Food and Drug Administration (FDA) for any indication. “Velico’s proprietary spray drying process produces a powdered plasma product that is stable at room temperature, easily reconstituted with sterile water, and transfusion ready within approximately 2.5 minutes.”

(Source: Vitalant & Velico Inc. [News Release](#), 2/26/25)

**The Blood Connection** has [announced](#) that it will open a new blood distribution and operations facility in Augusta, Ga. in May 2025. President and CEO Delisa English stated that, “[t]his new blood depot reflects our unwavering commitment to meeting the blood supply needs of hospitals and communities across Georgia. We’re excited to provide our hospital partners with faster, more specialized services, which are essential to saving lives.” According to a news release, the facility will feature a:

- “Blood Depot: [a] newly designed storage and distribution system that will streamline the collection and delivery process, ensuring faster and more reliable turnaround times for our hospital partners;
- Reference Lab: [u]pgraded systems and technology that support specialty blood cases, with advanced testing and improved blood matching; [and a]
- Donor Room: [m]ore space and resources for donors, offering a more comfortable and welcoming environment.”

(Source: The Blood Connection [News Release](#), 2/20/25)

(continued on page 4)

MEMBER NEWS (continued from page 3)

**New York Blood Center Enterprises (NYBCe)** has “[signed](#) a Letter of Intent” with Human Life CORD Japan Inc. to, “expand their manufacturing collaboration for mesenchymal stromal cells (MSCs) through Comprehensive Cell Solutions (CCS), a business unit of NYBCe.” This partnership seeks to, “drive innovation and enhance the global supply chain for next-generation umbilical cord tissue-derived MSCs. Upon finalizing the collaboration, Human Life CORD aims to achieve international harmonization of its manufacturing platform and establish a strong presence in North America. CCS emerges as the ideal partner, having steadily expanded its U.S. manufacturing footprint, invested in cutting-edge manufacturing technologies, and developed deep expertise in stem cell manufacturing. CCS’s Louisville, Kentucky site, as well as the facilities in Houston, Texas, and New York City, propels CCS into a national-scale contract development and manufacturing organization (CDMO).”

(Source: NYBCe [News Release](#), 2/27/25) 💧

**BRIEFLY NOTED**

**The U.S. Centers for Disease Control and Prevention (CDC)** [announced](#) that it is investigating five hospitalizations for, “cardiac (heart) or neurologic (nervous system) events following vaccination with Valneva’s chikungunya vaccine (Ixchiq) among people 65 years and older.” The agency explained that investigation findings will be, “further discussed with national immunization experts at an Advisory Committee on Immunization Practices (ACIP) meeting. [CDC] will provide more information as it becomes available. If you are traveling to an area with risk for chikungunya, talk to your healthcare provider about the possible benefits and risks for vaccination based on your age, destination, and other factors.” The FDA [approved](#) the Ixchiq in in November 2023 for adults at increased risk of exposure to the chikungunya virus.

(Source: CDC [Announcement](#), 2/25/25)

**Researchers from Johns Hopkins Kimmel Cancer Center, Vanderbilt University, and the University of California San Francisco** have [published](#) findings from a study that found that, “[a] modified bone marrow transplant procedure for sickle cell disease (SCD)” co-developed by the investigators can cure SCD. The paper is [available](#) in *NEJM Evidence* and results of the phase II study that took place at 19 sites in the U.S. between 2017 and 2021, “echoed the findings of [a] previously published [study](#) [which] highlighted a novel conditioning regimen for related HLA-haploidentical bone marrow transplantation (BMT). ‘Our earlier clinical trial, published in the journal *Blood* last year, showed that we can cure SCD in children and adults,’” said Michael DeBaun, MD, MPH, the J.C. Peterson, MD, chair and professor of Pediatrics at Vanderbilt University Medical Center, and director of the Vanderbilt-Meharry Center of Excellence in Sickle Cell Disease, in the announcement. “The new trial, conducted through the National Institutes of Health (NIH)-supported Blood and Marrow Transplant Clinical Trials Network, ‘is a direct extension of our previous study,’” explained Dr. DeBaun in the announcement. “The results are just as good, if not better, than gene therapy or gene editing therapy. More SCD patients with complicating medical conditions should be able to qualify for curative therapy because the new regimen has fewer toxic side effects and is about one-fifth the cost of myeloablative gene therapy.”

(Source: Vanderbilt University [Announcement](#), 2/27/25) 💧





**America's Blood Centers®**  
It's About *Life.*

## INSIDE ABC

*The programs and services described in the Inside ABC section are available to ABC member blood centers and their staffs only, unless otherwise specified.*

### **28<sup>th</sup> Annual Awards of Excellence Recipients to Be Honored at the ABC Annual Meeting**

Recipients of the America's Blood Centers' (ABC) 28th Annual Awards of Excellence will be recognized on March 10<sup>th</sup> and 11<sup>th</sup> during ABC Annual Meeting. Join us in congratulating the individuals, organizations, and advocates who have made outstanding contributions in promoting blood donation and improving transfusion medicine.

This year's recipients include:

- Thomas F. Zuck Lifetime Achievement Award – *Mary Townsend (Vitalant)*;
- Blood Community Advocate of the Year – *Billy Weales (The Blood Center)*;
- National Partner of the Year – *GLAAD*;
- Corporation of the Year Award – *East Penn Manufacturing (nominated by Miller-Keystone Blood Center)*;
- ITxM Award for Excellence in Technical Operations – *Evelyn Oyler (nominated by SunCoast Blood Centers)*;
- Larry Frederick Award – *Ruth Osburn, RN, BSN, COHN-S (nominated by Mississippi Blood Services)*;
- ABC Outstanding Blood Drive of the Year – *San Antonio National Pan-Hellenic Council (nominated South Texas Blood & Tissue)*; and
- ABC Outstanding Public Relations Campaign – *Vitalant's Social Medial Team (nominated by Vitalant)*

Additionally, Distinguished Service Awards will be presented to:

- *Daniela Hermelin, MD (ImpactLife)*
- *Lisa Entrikin (Rock River Valley Blood Center)*
- *Kim Kinsell, JD (LifeSouth Community Blood Centers)*
- *Theresa Pina (Gulf Coast Regional Blood Center)*
- *Robert Harper (SunCoast Blood Centers)*
- *Harpreet Sandhu (Standford Blood Center)*;
- *John B. Miller (LIFELINE Blood Services)*;
- *Stacy Sime (LifeServe Blood Center)*;
- *Wendell Jones (LifeShare Blood Center)*; and
- *D. Kip Kuttner, DO (Miller Keystone Blood Center)*

Thank you to all blood centers that submitted nominations.

(Source: [MCN 25-008](#))

(continued on page 6)

INSIDE ABC (continued from page 5)

### ***ADRP Trends in Donor Relations Study Opens***

The *ADRP Trends in Donor Relations Study* has [launched](#). This survey is a strategic tool for blood centers to evaluate and benchmark the performance of collection and recruitment operations and marketing strategies with your domestic and international peers. It streamlines and combines the previous ADRP Recruitment and Collections Survey and the ADRP Marketing Survey. ADRP is partnering with a third-party company, Dynamic Benchmarking, to improve the data collection and reporting experience. The confidentiality of your data and the information shared in this report is a top priority of ADRP and will only be disseminated in the aggregate and in accordance with anti-trust regulations. A key feature of the reporting platform is the ability to view how your operations compare to others using several dynamic filters, including blood center location, collection levels, and employee count. Only blood centers that participate in the survey will have access to this information. Participation in the study is open to all blood centers. Survey responses must be completed by March 24<sup>th</sup>. Please only submit one response per blood center. [Contact us](#) with questions.

### **Registration Open for ADRP Webinar: "Positive Impacts of a Global Pandemic: What Changed?"**

[Registration](#) is open for March 26<sup>th</sup> webinar at 1 p.m. EDT titled "[Positive Impacts of a Global Pandemic: What Changed?](#)" Hear Vitalant's Stephanie Radenz and LifeServe Blood Center's Danielle West discuss the significant changes and innovation implemented at their centers in the wake of the global pandemic, including adjustments to supply chains, the importance of a diversified vendor plan, pilot concepts with pseudo fixed sites for donor collections, and the benefits of virtual blood drives.

### **Registration Is Open for March 28<sup>th</sup> SMT Journal Club Webinar**

Registration is open for the next America's Blood Centers (ABC) Scientific, Medical, and Technical (SMT) Journal Club Webinar taking place on March 28<sup>th</sup> at 1 p.m. EDT. The webinar is free to all ABC members. An email announcement with a registration link and the articles to be reviewed can be found [here](#). A Continuing Medical Education (CME) credit (1.0) is now offered for all ABC SMT Journal Club webinars.

### **Still Time Register for the 2025 ABC Annual Meeting**

Join us for the 63<sup>rd</sup> ABC [Annual Meeting](#) in Arlington, Va. [Registration](#) is open and the [schedule is available](#). Hear *POLITICO*'s Director of Regulatory Research Laura DiAngelo, MPH deliver the keynote as she addresses the impact of the 2024 Presidential and Congressional elections on the regulatory and congressional landscape. Meeting attendees will gain insights into how the administration's policy agenda and approach to regulation will impact the blood community, allowing your organization to stay ahead of the curve. This event will also explore the latest developments in advocacy, leadership, operations, science, and medicine, connecting and preparing your C-suite and senior leadership for the most critical topics facing your blood center. Following the success of last year's revamped format and expanded content offerings, we will continue this approach in 2025. [Sponsorship opportunities](#) are also still available. Please [contact us](#) with any questions as we look forward to seeing you!

(continued on page 7)



INSIDE ABC (continued from page 6)

## Register for the 2025 ADRP Annual Conference

[Register now](#) for the [2025 ADRP Annual Conference](#) in Oklahoma City, Oklahoma, from May 6th to 8th at the Omni Oklahoma City Hotel. Remember to [book your hotel room](#) by April 11th for the discounted rate. This conference offers a chance to learn about industry trends, share ideas, and connect with other donor recruitment, donor services, collections, marketing, and communications professionals. Join more than 400 of your peers by participating in pre-conference workshops, attending compelling educational sessions, engaging in roundtable discussions, and exploring an expansive exhibit hall filled with innovative solutions. [Seize this extraordinary opportunity](#) to learn, share, and grow within the blood community. 💧

## INFECTIOUS DISEASE UPDATES

### MEASLES

The U.S. Centers Disease Control and Prevention (CDC) [reported](#) on February 27<sup>th</sup> that there have been three measles outbreaks (defined as three or more related cases) in the U.S. this year resulting in 164 reported cases and one death, the first in the U.S. since 2015. According to the agency the cases have been reported by: Alaska, California, Georgia, Kentucky, New Jersey, New Mexico, New York City, Rhode Island, and Texas with 93 percent of cases (153 of 164) are outbreak-associated. In 2024, the U.S. reported 285 total cases. The CDC published a [statement](#) explaining, “[the agency] continues to be in close communication with Texas health authorities about the measles outbreak in West Texas, following the death of a child. [The] U.S. Department of Health and Human Services (HHS) is providing technical assistance, laboratory support, vaccines, and therapeutic medication as needed to the Texas Department of State Health Services and New Mexico Department of Health, which are leading the responses to the outbreaks in their jurisdictions. Measles outbreaks are occurring globally, particularly in Asia, which means that there is an increased likelihood of cases among unvaccinated travelers returning to the U.S., which we saw in the February 19 case of an Orange County, California resident returning from Asia. Vaccination remains the best defense against measles infection. Measles does not have a specific antiviral treatment. [HHS] Secretary Kennedy has spoken directly to Governor Abbott, Commissioner of the Texas Department of State Health Services Dr. Jennifer A. Shuford, and other public health officials to express HHS’ willingness to support local efforts in dealing with the outbreak.” Transfusion-transmission of measles has never been demonstrated, and any risk to the blood supply is believed to be theoretical.

(Sources: CDC [Announcement](#), 2/27/25; CDC [Statement](#), 2/27/25)

### MPOX


The World Health Organization’s (WHO) International Health Regulations (2005) Emergency Committee [held](#) a February 25<sup>th</sup> meeting and determined that a surge in mpox that began in 2024 continues to be a public health emergency of international concern (PHEIC). The agency published data that revealed, “[i]n the past twelve months, as of February 23<sup>rd</sup>, 22 countries have reported 21,598 confirmed cases, including 81 deaths. The three countries with the majority of the cases in the last 12 months are Democratic Republic of the Congo (n=13,869), Burundi (n=3,543), and Uganda (n=3,391).”

Additionally, the committee published a revised set of temporary recommendations for nations that are experiencing” mpox transmission, sustained community transmission, and where here are clusters of cases or sporadic travel-related cases of mpox clade Ib.”

(continued on page 8)

INFECTIOUS DISEASE UPDATES (continued from page 7)

According to a previous U.S. Food and Drug Administration (FDA) [communication](#), “there have been no reports of transmission of mpox virus through blood transfusion and the risk of transfusion-transmission remains theoretical. [Routine] measures used to determine blood donor eligibility prevent individuals with symptomatic infections from donating blood. [T]hese safeguards are likely to identify individuals who present to donate who are diagnosed with mpox virus or who are currently at the greatest risk for infection with mpox virus. Given the robustness of the existing safeguards for blood safety FDA does not recommend that blood establishments ask donors additional, specific questions about possible exposure to mpox virus. Further, FDA does not recommend using laboratory diagnostic tests to screen blood donors for mpox virus.”



(Source: WHO [Announcement](#), 2/27/25) 💧

**GLOBAL NEWS**

**NHS Blood and Transplant, the national blood provider for England and transplant services for the United Kingdom (UK), and Queen May University have [announced](#) the Propheesy-2 trial. It aims to see if treating heart surgery patients who bleed post-surgery with clotting factor produces better outcomes than treatment with fresh frozen plasma (FFP).** NHSBT noted in the announcement that the trial will include 496 participants over a two-year period who are randomized with measures for better outcomes including, mortality, infection, and organ injury. Professor Laura Green, the chief investigator for the trial, added in the announcement, “[o]f the 250,000 Fresh Frozen Plasma (FFP) doses that NHS Blood and Transplant sends to hospitals every year, more than 30,000 (12 percent) are used to treat bleeds from heart surgery. [While] PCC may stop bleeding faster and lead to fewer complications, [there] is a worry that PCC can also increase the risks of developing blood clots by making the blood clot too quickly. PCC use is increasing in the UK, so it is important to conduct a clinical trial to compare the two treatments. No previous trial has compared these two treatments in cardiac surgery, so we’re excited that the first three sites have opened, and the first patient has been randomi[z]ed.” Funding for the trial is being provided by a grant from National Institute of Health Care Research’s Health Technology Assessment program.

Source: NHSBT [Announcement](#), 2/25/25)

(continued on page 9)



GLOBAL NEWS (continued from page 8)

**The Ghana National Blood Service (GNBS) will [open](#) blood centers in all 16 regions across the country, according to a report from *The Business & Financial Times*.** The publication stated that blood service’s goal is to, “to ensure availability and accessibility of blood for patients.” GNBS Chief Executive Officer Dr. Shirley Owusu-Ofori explained that the centers will, “mobil[ize] voluntary donors, recruit[t] and educat[e] them to collect blood and distribute it to the hospitals. This initiative will bring blood to patients ‘so that no one dies [from] a lack of blood.’”

(Source: *The Business & Financial Times*, “[National Blood Service to establish regional blood centres](#),” 2/20/25) ◆

## COMPANY NEWS

**Terumo Blood and Cell Technologies** (Terumo BCT) has [collaborated](#) with the **National Alliance of Sickle Cell Centers** (NASCC) to develop the “Bet on Blood for Sickle Cell Disease” partnership. According to a company news release, this initiative aims to, “improve the lives of people with sickle cell disease (SCD) by addressing gaps in access to blood transfusion therapy and helping educate healthcare providers about how transfusion therapy can be used to improve patient outcomes.” Through the partnership, the organizations will, “focus on comprehensive strategies to address systemic challenges in SCD care related to blood therapy and cellular therapies [by:]

- “[o]ptimizing access to blood, blood utilization and vascular access techniques;
- [e]nhancing practices for blood-based therapies, specifically automated red cell exchange;
- [e]xpanding education and awareness about critical blood therapies; [and]
- [c]onnecting industry, patient groups, and caregivers to develop comprehensive solutions.”

NASCC is a, “It is a network of recognized SCD centers including healthcare professionals, mental health providers, nurses, social workers, and many other team members focused on promoting best practices in clinical care and ensuring access to high-quality care for SCD patients.”

(Source: Terumo BCT [News Release](#), 2/25/25)

**Blood Centers of America** (BCA) and **Asimily** have [partnered](#) to provide BCA members with access to Asimily’s cybersecurity platform. Specifically, a news release explained that, “[t]his partnership makes Asimily’s comprehensive [l]ab, [m]edical [d]evice, and internet of things (IoT) security and risk management platform directly available to all BCA members, enabling blood centers [to:]

- [m]onitor all connected devices, including critical blood testing and processing equipment;
- [r]educe their threat surface by mitigating exploitable vulnerabilities;
- [d]etect and respond to threats before they impact blood center operations;
- [a]utomate security operations with healthcare-optimized workflows;
- [m]eet stringent compliance requirements and follow U.S. Food and Drug Administration guidance; [and]
- [s]afeguard sensitive patient data and intellectual property.”

(Source: Asimily [News Release](#), 2/27/25) ◆



## CALENDAR

**Note to subscribers:** Submissions for a free listing in this calendar (published weekly) are welcome. Send information to [newsletter@americasblood.org](mailto:newsletter@americasblood.org). (For a more detailed announcement in the weekly "Meetings" section of the newsletter, please include program information.)

### 2025

Mar. 10-12. **ABC Annual Meeting, Arlington, Va.** [Registration](#) is open. More information available [here](#).

Mar. 26. ADRP Webinar: "Positive Impacts of a Global Pandemic: What Changed?" [Registration](#) is open. More information is available [here](#).

Mar. 28. **ABC Scientific, Medical, and Technical (SMT) Journal Club Spring Webinar.** More information and a link to registration are available to ABC members [here](#).

May 6-8. **2025 ADRP Annual Conference, Oklahoma City, Okla.** [Registration](#) is open. More information available [here](#).

May 14-15. **International Plasma and Fractionation Association (IPFA)/Paul-Ehrlich Institut[e] (PEI) 30<sup>th</sup> International Workshop on Surveillance and Screening of Blood-borne Pathogens, Heidelberg, Germany.** [Registration](#) is open. More information available [here](#).

May 20-21. **International Plasma Protein Congress, Warsaw, Poland.** More information is coming soon.

June 1-4. **International Society of Blood Transfusion (ISBT) 35<sup>th</sup> Regional Congress, Milan, Italy.** [Registration](#) is open. More information available [here](#).

June 10-11. **ABC Advocacy Workshop, Washington, D.C.** More information is coming soon.

June 25-26. **HHS ODP TBDAIC Community Engagement Meeting (Hybrid), Portland, Maine.** More information is coming soon.

June 30-July 1. **HHS Administration for Strategic Preparedness and Response (ASPR) Biomedical Advanced Research and Development Authority (BARDA) Industry Day 2025 (Hybrid), Washington, D.C.** More information available [here](#).

Sept. 10. **FDA CBER Office of Blood Research and Review (OBRR) Public Webinar: FDA Review of Biologics License Applications for Blood and Source Plasma (Virtual).** More information is coming soon.

Oct. 12-15. **American Association of Tissue Banks (AATB) Annual Meeting, Atlanta, Ga.** More information is coming soon.

Oct. 25-28. **AABB Annual Meeting, San Diego, Calif.** More information is coming soon.

Nov. 17-20. **American Society for Clinical Pathology (ASCP) Annual Meeting, Atlanta, Ga.** [Registration](#) is open. More information available [here](#). 💧

## CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC members. There are charges for non-members: \$139 per placement for ABC Newsletter subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: [newsletter@americasblood.org](mailto:newsletter@americasblood.org)

## POSITIONS

**Assistant Manager - Product Quality Control (Carter BloodCare).** Principal Accountability: The Assistant Manager Product Quality Control reports to the Manager of Product Quality Control and will be responsible for all daily, routine departmental activities and operations, consulting with the Manager, as needed. This position will oversee strict fiscal adherence to the budget and other administrative activities for the department, as assigned by the Manager, Technical Director, or Medical Director. The Assistant Manager is able and willing to perform any departmental task, as needed, to ensure efficient workflow within the department. Education: Bachelor of Science Degree. Minimum MT/MLS ASCP, or equivalent, required. Experience: Working knowledge of Product Quality Control instrumentation and parameters associated with donor collections. Strong working knowledge of blood bank policies and procedures Comprehensive problem-solving skills. Good written and verbal communication skills. Excellent interpersonal and conflict resolution skills. Very strong customer service practices. Advanced computer skills. Comprehensive knowledge of administrative functions, including budget activities. Effective organizational skills, to include the ability to organize and prioritize workload, attention to detail, and consistently follow through with a commitment to excellence. Equal Opportunity Employer: Disability/Veteran Apply at <http://www.carterbloodcare.org/>, click Careers & search for job Assistant Manager Product Quality Control.

**Medical Technologist.** Join Suncoast Blood Centers – Where Every Drop Saves Lives! Sarasota, FL. We're looking for a passionate and skilled Medical Technician (Blood Banking) to be part of our mission-driven team! You'll play a vital role in blood collection, processing, compatibility testing, and transfusion services—all while ensuring top safety and compliance standards. For 75+ years, Suncoast Blood Centers has been a lifeline for our community, delivering lifesaving blood products with dedication and care. We offer amazing benefits, generous PTO, and a sign-on bonus! Make a difference—apply today! To apply: [Careers - SunCoast Blood Centers](#)

**Vice President of Operations.** LifeSouth Community Blood Centers is currently looking for a highly driven individual with outstanding leadership, communication, and interpersonal skills to join our Executive Team as Vice President of Operations. This is a senior leadership role who reports directly to the Chief Operating Officer and is responsible for overseeing and driving the operational effectiveness of LifeSouth Community Blood Centers across a multi-state footprint set by executive leadership. In this position you will develop, implement, and lead strategic initiatives to enhance blood donations, blood processing, and blood distribution while ensuring operational efficiency and compliance with regulatory standards. This position is also responsible for maintaining optimal staffing ratios, overseeing training programs,

and ensuring continuous operational growth and innovation. Join our team and help us continue our dedication to making sure blood is there when you or your family is in need. Visit our careers page to learn more about this position, and [apply here!](#)

**Chief Medical Officer (CMO).** Carter BloodCare seeks a dynamic **Chief Medical Officer (CMO)** to lead medical and technical operations and ensure excellence in transfusion medicine, cellular therapy, and donor care. As a key executive team member, the CMO will drive innovation, compliance, and strategic growth. **Why Carter BloodCare?** Mission-Driven Work: Your leadership directly impacts patients in need. Executive Leadership: Collaborate with the CEO and executive team to shape policies and strategy. Industry Influence: Represent Carter BloodCare as a thought leader in transfusion medicine. Growth & Innovation: Lead research initiatives and partnerships with medical institutions. **Key Responsibilities:** Oversee medical services, ensuring safety, compliance, and quality. Act as CLIA Lab Director for high and moderate-complexity testing labs. Serve as one of the medical and scientific faces of Carter BloodCare. Lead and mentor Medical Directors, fostering a culture of excellence. Guide organizational strategy and budgeting. Advance clinical research, academic collaborations, and medical education initiatives. **What We're Looking For:** M.D. or D.O. (or equivalent) with board certification in transfusion medicine or a related field. Eligibility for a Texas medical license and willingness to obtain additional state licenses as needed. 7+ years of experience in blood banking/transfusion medicine or related field. 3+ years of leadership experience. **Apply today:** [www.carterbloodcare.org/careers](http://www.carterbloodcare.org/careers)

**Medical Laboratory Scientist - Blood Bank (Overnight).** LifeSouth Community Blood Centers is looking for an experienced Medical Laboratory Scientist, with a passion for making a difference, to join our Immunohematology Reference Laboratory team in Atlanta, GA. The position is responsible for following established policies and procedures, identifying problems that may adversely affect test performance or reporting of test results, and either correct the problems or immediately notify a supervisor, manager, or director. The Medical Laboratory Scientist will resolve complex immunohematology and compatibility problems to provide the safest donor blood for the patients in our community. We focus on providing the best possible customer service. Join our team and help us continue our dedication to making sure blood is there when you or your family is in need. Visit our careers page to learn more about this position, and [apply here!](#)

(continued on page 12)

POSITIONS (continued from page 11)

**Associate Medical Director/Medical Director (Versiti Blood Center of Ohio).** Serve as the physician face of Versiti and Versiti Ohio, translating complex medical issues to educate other physicians, support staff and the public. Opportunities in educational initiatives and clinical/applied research are available within Versiti and with our affiliated health systems. As part of the Versiti physician team you will have the opportunity to participate in clinical research projects with investigators at our world-renowned diagnostic laboratory and blood research institute. Joining our Medical Science Institute transfusion medicine physician team will provide you with a uniquely diverse and collaborative experience. Requirements: MD or DO Degree. Board certified/eligible in Blood Banking/Transfusion Medicine. At least three years of experience in blood center/transfusion medicine practice preferred. Licensed or eligible for an Ohio and Indiana; other state licenses may be required. Driver's License in good standing. Please click [here](#) to read the full job description and apply.

**Medical Director/Associate Medical Director.** Carter BloodCare seeks a passionate and dedicated **Medical Director/Associate Medical Director** to join our mission driven team in North Texas. This role offers the opportunity to collaborate with a dynamic group of medical professionals and lead innovative initiatives that save lives every day. As Medical Director/Associate Medical Director, you'll play a pivotal role in the medical and technical oversight of blood centers, transfusion services, and advanced biotherapies. Working closely with the Chief Medical Officer and fellow directors, you will ensure our operations remain at the forefront of transfusion medicine. From providing consultative expertise to fostering relationships with healthcare providers, your work will directly influence patient care across the region. Carter BloodCare seeks candidates with an MD, DO, or equivalent degree, board certification/eligibility in Blood Banking/Transfusion Medicine, and qualified for an unrestricted medical license in Texas. The successful candidate will bring expertise, compassion, and a collaborative spirit to this vital role with strong knowledge and experience in blood banking and/or advanced biotherapies. This is a chance to join an organization dedicated to excellence and innovation in transfusion medicine. Apply at [//www.carterbloodcare.org/careers](http://www.carterbloodcare.org/careers). Carter BloodCare is an EEO/Affirmative Action employer.

**Assistant/Associate/Full Professor, Clinical Track (Hoxworth Blood Center).** Hoxworth Blood Center (HBC) was founded in 1938 and serves more than 30 hospitals in 18 counties in Ohio, Kentucky, and Indiana. Annually, HBC collects more than 100,000 units of blood from local donors to help save the lives of patients in area hospitals. HBC is located within the University of Cincinnati (UC), College of Medicine, and is seeking an academic physician to advance clinical services and research in Blood Banking and Transfusion Medicine. The rank of the clinical track appointment is open and will be commensurate with the experience and professional accomplishments of the selected applicant. Essential Functions: Provide clinical blood banking/transfusion medicine coverage in an active academic transfusion service supporting a robust academic teaching hospital specializing in hematology/oncology, high risk obstetrics, organ transplantation and surgery; including a Level I Trauma Center. Provide medical coverage for a large regional independent blood collection center with an active apheresis program supporting cell therapy collections. Engage in the training of Transfusion Medicine fellows, pathology residents, and rotating fellows, residents, and medical students. Minimum Requirements: MD or MD/PhD; Board eligibility or Board certification in Blood Banking/Transfusion Medicine; and active or eligible for a State of Ohio Medical License. Click [here](#) to view the full job description and apply. EOE ♠